Comment from American Society of Transplant Surgeons

Summary: The American Society of Transplant Surgeons (ASTS) supports the FDA's interest in drug repurposing to expand access to immunosuppressive drugs for transplant recipients. They argue that creating a pathway to repurpose drugs already approved for kidney transplants could eliminate significant reimbursement barriers for patients receiving extra-renal transplants.